Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efineptakin alfa - Genexine

Next Previous
Drug Profile

Efineptakin alfa - Genexine

Alternative Names: Efineptakin alfa NT-I7; GX I7; HyLeukin; HyLeukin-7™; IL-7 Hybrid Fc; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT I7; Recombinant human IL-7-hyFc; Recombinant human interleukin-7 hybrid Fc; rhIL-7 - Genexine/NovaBridge Biosciences; rhIL-7-hyFc; TJ 107

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Bristol-Myers Squibb; Fred Hutchinson Cancer Research Center; Genexine; Merck & Co; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; National Institute of Neurological Disorders and Stroke; NeoImmuneTech; NovaBridge Biosciences; PT Kalbe Genexine Biologics; Roche; Washington University School of Medicine; Yonsei University
  • Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Radioprotectives; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Interleukin 7 replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Glioblastoma; Pancreatic cancer; Idiopathic CD4-positive T-lymphocytopenia; Progressive multifocal leukoencephalopathy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; COVID 2019 infections; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
  • Phase I/II Lymphopenia; Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours
  • Phase I B-cell lymphoma; Multiple myeloma
  • Preclinical Acute radiation syndrome
  • No development reported Anal cancer; Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Cervical intraepithelial neoplasia; Colorectal cancer; Diffuse large B cell lymphoma; Human papillomavirus infections; Idiopathic CD4-positive T-lymphocytopenia; Kaposi's sarcoma; Lymphoma; Ovarian cancer; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 19 Aug 2026 Efineptakin alfa licensed to Tolerance Bio in the Americas and Europe
  • 19 Aug 2026 Tolerance Bio plans a phase II trials for Immunodeficiency-disorders
  • 11 Jun 2026 NeoImmuneTech terminates a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IM) (NCT04984811)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top